Advanced Science (Mar 2024)
Extracellular Vesicular Analysis of Glypican 1 mRNA and Protein for Pancreatic Cancer Diagnosis and Prognosis
- Hong Li,
- Chi‐Ling Chiang,
- Kwang Joo Kwak,
- Xinyu Wang,
- Sital Doddi,
- Lakshmi V. Ramanathan,
- Sun M. Cho,
- Ya‐Chin Hou,
- Tai‐Shan Cheng,
- Xiaokui Mo,
- Yueh‐Shih Chang,
- Hui‐Lan Chang,
- Weiming Cheng,
- Wei‐Ni Tsai,
- Luong T. H. Nguyen,
- Junjie Pan,
- Yifan Ma,
- Xilal Y. Rima,
- Jingjing Zhang,
- Eduardo Reategui,
- Yeh‐Shiu Chu,
- Peter Mu‐Hsin Chang,
- Pei‐Hung Chang,
- Chi‐Ying F. Huang,
- Cheng‐Hsu Wang,
- Yan‐Shen Shan,
- Chung‐Pin Li,
- Martin Fleisher,
- L. James Lee
Affiliations
- Hong Li
- Department of Chemical and Biomolecular Engineering Ohio State University Columbus OH 43210 USA
- Chi‐Ling Chiang
- Department of Chemical and Biomolecular Engineering Ohio State University Columbus OH 43210 USA
- Kwang Joo Kwak
- Spot Biosystems Ltd. Columbus OH 43212 USA
- Xinyu Wang
- Department of Chemical and Biomolecular Engineering Ohio State University Columbus OH 43210 USA
- Sital Doddi
- Department of Laboratory Medicine Memorial Sloan Kettering Cancer Center New York NY 10065 USA
- Lakshmi V. Ramanathan
- Department of Laboratory Medicine Memorial Sloan Kettering Cancer Center New York NY 10065 USA
- Sun M. Cho
- Department of Laboratory Medicine Memorial Sloan Kettering Cancer Center New York NY 10065 USA
- Ya‐Chin Hou
- Institute of Clinical Medicine College of Medicine National Cheng Kung University Tainan 70101 Taiwan
- Tai‐Shan Cheng
- Institute of Biopharmaceutical Sciences National Yang Ming Chiao Tung University Taipei 11221 Taiwan
- Xiaokui Mo
- Center for Biostatistics Ohio State University Columbus OH 43210 USA
- Yueh‐Shih Chang
- School of Traditional Chinese Medicine College of Medicine Chang Gung University Taoyuan 33302 Taiwan
- Hui‐Lan Chang
- Division of Gastroenterology and Hepatology Department of Medicine Taipei Veterans General Hospital Taipei 11217 Taiwan
- Weiming Cheng
- Institute of Biopharmaceutical Sciences National Yang Ming Chiao Tung University Taipei 11221 Taiwan
- Wei‐Ni Tsai
- Institute of Biopharmaceutical Sciences National Yang Ming Chiao Tung University Taipei 11221 Taiwan
- Luong T. H. Nguyen
- Department of Chemical and Biomolecular Engineering Ohio State University Columbus OH 43210 USA
- Junjie Pan
- Department of Chemical and Biomolecular Engineering Ohio State University Columbus OH 43210 USA
- Yifan Ma
- Department of Biomedical Engineering Ohio State University Columbus OH 43210 USA
- Xilal Y. Rima
- Department of Chemical and Biomolecular Engineering Ohio State University Columbus OH 43210 USA
- Jingjing Zhang
- Department of Chemical and Biomolecular Engineering Ohio State University Columbus OH 43210 USA
- Eduardo Reategui
- Department of Chemical and Biomolecular Engineering Ohio State University Columbus OH 43210 USA
- Yeh‐Shiu Chu
- Brain Research Center National Yang Ming Chiao Tung University Taipei 11221 Taiwan
- Peter Mu‐Hsin Chang
- Institute of Biopharmaceutical Sciences National Yang Ming Chiao Tung University Taipei 11221 Taiwan
- Pei‐Hung Chang
- School of Traditional Chinese Medicine College of Medicine Chang Gung University Taoyuan 33302 Taiwan
- Chi‐Ying F. Huang
- Institute of Biopharmaceutical Sciences National Yang Ming Chiao Tung University Taipei 11221 Taiwan
- Cheng‐Hsu Wang
- Division of Hematology‐Oncology Department of Internal Medicine Chang Gung Memorial Hospital Keelung 20401 Taiwan
- Yan‐Shen Shan
- Institute of Clinical Medicine College of Medicine National Cheng Kung University Tainan 70101 Taiwan
- Chung‐Pin Li
- Division of Gastroenterology and Hepatology Department of Medicine Taipei Veterans General Hospital Taipei 11217 Taiwan
- Martin Fleisher
- Department of Laboratory Medicine Memorial Sloan Kettering Cancer Center New York NY 10065 USA
- L. James Lee
- Department of Chemical and Biomolecular Engineering Ohio State University Columbus OH 43210 USA
- DOI
- https://doi.org/10.1002/advs.202306373
- Journal volume & issue
-
Vol. 11,
no. 11
pp. n/a – n/a
Abstract
Abstract Detecting pancreatic duct adenocarcinoma (PDAC) in its early stages and predicting late‐stage patient prognosis undergoing chemotherapy is challenging. This work shows that the activation of specific oncogenes leads to elevated expression of mRNAs and their corresponding proteins in extracellular vesicles (EVs) circulating in blood. Utilizing an immune lipoplex nanoparticle (ILN) biochip assay, these findings demonstrate that glypican 1 (GPC1) mRNA expression in the exosomes‐rich (Exo) EV subpopulation and GPC1 membrane protein (mProtein) expression in the microvesicles‐rich (MV) EV subpopulation, particularly the tumor associated microvesicles (tMV), served as a viable biomarker for PDAC. A combined analysis effectively discriminated early‐stage PDAC patients from benign pancreatic diseases and healthy donors in sizable clinical from multiple hospitals. Furthermore, among late‐stage PDAC patients undergoing chemotherapy, lower GPC1 tMV‐mProtein and Exo‐mRNA expression before treatment correlated significantly with prolonged overall survival. These findings underscore the potential of vesicular GPC1 expression for early PDAC screenings and chemotherapy prognosis.
Keywords
- Glypican 1 mRNA in exosomes and protein in tumor‐associated microvesicles as a dual biomarker
- immune lipoplex nanoparticle biochip assay
- PDAC screening and chemotherapy prognosis
- single extracellular vesicle analysis
